Issues in pharmaceutical lotteries: the case of interferon beta-1b.
Manocchia
M
M
Tufts Center for the Study of Drug Development, Tufts University, USA. michael.manocchia@es.nemc.org
Lasagna
L
L
D000276:Adjuvants, Immunologic / Q000600:supply & distribution* / Q000627:therapeutic use*; D001709:Biotechnology / Q000331:legislation & jurisprudence; D017277:Drug Approval; D017408:Guidelines as Topic; D017048:Health Care Costs; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000096:biosynthesis / Q000600:supply & distribution* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D010817:Physician-Patient Relations; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a